Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2023-11-01
Ráidu:	Frontiers in Oncology
Fáttát:	clinical outcome toxicity low-and intermediate-risk radiotherapy prostate cancer stereotactic body radiation
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!